Diabetes: Insulin signal meets SIRT1 at AKT

Nature Reviews Endocrinology

Volumn 8, Issue 3, 2012, Pages 131-132

  Horio, Yoshiyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PROTEIN KINASE B; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

ANIMAL; ENZYMOLOGY; GENETICS; GLUCONEOGENESIS; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; HUMANS; INSULIN; INSULIN RESISTANCE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84865139517     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.208     Document Type: Article

References (9)

1. Wang, R. H. et al. Hepatic Sirtl deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J. Clin. Invest. 121, 4477-4490 (2011).
2. Houstis, N., Rosen, E. D. and Lander, E. S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948 (2006).
3. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-lalpha and SIRT1. Nature 434, 113-118 (2005).
4. Liu, Y et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456, 269-273 (2008).
5. Sundaresan, N. R. et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci. Signal. 4, ra46 (2011).
6. Schenk, S. et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 121, 4281-4288 (2011).
7. Yoshino, J., Mills, K. F., Yoon, M. J. and Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528-536 (2011).
8. Sun, C. et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6, 307-319 (2007).
9. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).